CollPlant Biotechnologies
CLGN
2 hedge funds and large institutions have $52K invested in CollPlant Biotechnologies in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
91% less capital inflows, than outflows
Capital inflows: $67.7K | Capital outflows: $781K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$58.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Meitav Investment House
Bene-Beraq,
Israel
|
-$780K |
| 2 |
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$1K |
CLGN Hedge Fund Activity: Q2 2019 in Review
2 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q2 2019, worth a combined $52K — down 93% from $781K a quarter earlier.
Fund positioning in CLGN was balanced in Q2 2019: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $58.4K. The largest seller was Meitav Investment House, exiting entirely with an estimated $780K sold.
- 2 institutional investors held CollPlant Biotechnologies (CLGN) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $52K of CollPlant Biotechnologies stock for Q2 2019, down 93% quarter-over-quarter.
- 2 funds opened new CollPlant Biotechnologies positions in Q2 2019 and 2 closed out, a net change of 0 holders.
- The largest CollPlant Biotechnologies buyer in Q2 2019 was Citadel Advisors, an estimated $58.4K added.
- The largest CollPlant Biotechnologies seller in Q2 2019 was Meitav Investment House, an estimated $780K sold.
Based on aggregated 13F filings for Q2 2019.